Scarica l'app Stockscreener
36.27
0.68%
-0.25
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$36.52
Aprire:
$37.32
Volume 24 ore:
6.61M
Relative Volume:
2.51
Capitalizzazione di mercato:
$6.24B
Reddito:
$1.64B
Utile/perdita netta:
$121.85M
Rapporto P/E:
23.55
EPS:
1.54
Flusso di cassa netto:
$-480.40M
1 W Prestazione:
-42.89%
1M Prestazione:
-34.82%
6M Prestazione:
-70.18%
1 anno Prestazione:
-72.59%
Intervallo 1D:
$35.93
$39.66
Intervallo di 1 settimana:
$35.46
$64.80
Portata 52W:
$35.46
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Nome
Sarepta Therapeutics Inc
Settore
Industria
Telefono
617-274-4000
Indirizzo
215 FIRST STREET, CAMBRIDGE, MA
Confronta SRPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
36.27 | 6.24B | 1.64B | 121.85M | -480.40M | 1.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Iniziato | Wells Fargo | Overweight |
| 2025-04-02 | Aggiornamento | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-11-27 | Reiterato | Needham | Buy |
| 2024-11-25 | Iniziato | H.C. Wainwright | Sell |
| 2024-11-07 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Iniziato | Jefferies | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-07-29 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-05-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Iniziato | BMO Capital Markets | Outperform |
| 2023-12-13 | Ripresa | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-21 | Iniziato | Wedbush | Outperform |
| 2023-10-31 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-04 | Iniziato | Citigroup | Buy |
| 2023-03-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Reiterato | BTIG Research | Buy |
| 2022-12-16 | Aggiornamento | UBS | Neutral → Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Reiterato | Needham | Buy |
| 2021-12-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-08-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-01-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-11 | Downgrade | UBS | Buy → Neutral |
| 2021-01-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Iniziato | Mizuho | Buy |
| 2019-11-01 | Iniziato | Guggenheim | Buy |
| 2019-08-21 | Reiterato | Needham | Buy |
| 2019-07-09 | Reiterato | Morgan Stanley | Overweight |
| 2019-07-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-11 | Reiterato | Credit Suisse | Outperform |
| 2018-10-12 | Iniziato | Bernstein | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Reiterato | RBC Capital Mkts | Outperform |
| 2018-09-14 | Ripresa | BofA/Merrill | Buy |
| 2018-09-06 | Iniziato | Credit Suisse | Outperform |
| 2018-08-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Reiterato | Robert W. Baird | Outperform |
| 2018-06-20 | Reiterato | Needham | Buy |
| 2018-06-19 | Reiterato | H.C. Wainwright | Buy |
Mostra tutto
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
These 3 Biotech Picks Can Combat Sarepta Losses After Unexpected Death - TheStreet Pro
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta ... - Bluefield Daily Telegraph
Is Sarepta Therapeutics, Inc. (SRPT) The Best Stock That Will Bounce Back? - Yahoo Finance
Sarepta’s Week Goes From Bad to Worse on FDA Fears, Outlook Cut - Bloomberg.com
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference | SRPT Stock News - GuruFocus
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference - Business Wire
Sarepta Therapeutics (SRPT) Faces Investment Rating Downgrade - GuruFocus
Sarepta price target lowered to $125 from $183 at Needham - Yahoo Finance
Sarepta Therapeutics (SRPT) Price Target Lowered by Wells Fargo | SRPT Stock News - GuruFocus
UBS Cuts Price Target on Sarepta Therapeutics to $85 From $188, Keeps Buy Rating - marketscreener.com
The Consensus EPS Estimates For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Fell A Lot - simplywall.st
Evercore ISI cuts Sarepta stock rating, slashes price target - Investing.com
Sarepta Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Sarepta (SRPT) Downgraded by Evercore ISI with New Price Target | SRPT Stock News - GuruFocus
Why Sarepta Therapeutics, Inc. (SRPT) Nosedived on Wednesday - Insider Monkey
Beware of Sarepta, CRISPR Therapeutics, and More - Baystreet.ca
Long-Term Potential and Strategic Developments Drive Buy Rating for Sarepta Therapeutics Despite Short-Term Challenges - TipRanks
Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT) - Yahoo Finance
Sarepta Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment - insights.citeline.com
Some unshod by Prasad nod as CBER change socks stocks - BioWorld MedTech
The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low - Investor's Business Daily
Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating - Seeking Alpha
Sarepta Therapeutics (SRPT) Stock Trades Down, Here Is Why - Yahoo Finance
Sarepta Therapeutics Stock Plunges on Guidance Cut. Its ‘Moneymaker’ Is Under Fire. - Barron's
Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up - Benzinga
BMO Capital cuts Sarepta stock target to $120, maintains Outperform - Investing.com
Cantor Fitzgerald cuts Sarepta stock target to $81 - Investing.com
Sarepta Therapeutics: Lowered Elevidys Guidance Warrant Ratings Downgrade (NASDAQ:SRPT) - Seeking Alpha
TD Cowen cuts Sarepta stock target, maintains Buy rating - Investing.com
Sarepta shares plummet as lower sales outlook adds to gloom over FDA’s new biologics hire - BioPharma Dive
Sarepta (SRPT) Target Price Lowered by Needham Amid Leadership Change Concerns | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Price Target Reduced by Piper Sandler | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT): Analyst Lowers Price Target but Maintains Rating | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Target Price Revised by Cantor Fitzgerald | SRPT Stock News - GuruFocus
Sarepta (SRPT) Price Target Cut by RBC Capital Amid Elevidys Challenges | SRPT Stock News - GuruFocus
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Benzinga
Sarepta Therapeutics (SRPT) Sees Price Target Reduced by Analyst | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Price Target Lowered by Morgan Stanley | SRPT Stock News - GuruFocus
Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results - Benzinga
Sarepta Therapeutics (SRPT) Price Target Lowered by Needham Analyst | SRPT Stock News - GuruFocus
SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut - Yahoo Finance
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2025 Earnings Call Transcript - Insider Monkey
Sarepta (SRPT) Faces Price Target Reduction Amid Revenue Challenges | SRPT Stock News - GuruFocus
Sarepta stock target cut to $40 by H.C. Wainwright on slow sales - Investing.com
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Sarepta (SRPT) Target Price Reduced Amid Regulatory Concerns | SRPT Stock News - GuruFocus
Sarepta tries to quell concerns over DMD gene therapy Elevidys as patients delay treatment after death report - Fierce Pharma
Guggenheim Adjusts Sarepta (SRPT) Price Target Amid Uncertainty | SRPT Stock News - GuruFocus
S&P 500 Futures Rise in Premarket Trading; Sarepta Therapeutics, OneStream Lag - Barron's
Sarepta shares fall amid FDA’s CBER appointment and weak Elevidys sales - Yahoo Finance
Sarepta Therapeutics Inc Azioni (SRPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):